Portola Pharmaceuticals

Aug 22, 2019

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Aug 07, 2019

Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 06, 2019

Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe

Aug 05, 2019

U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa

Jul 17, 2019

Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

Jun 19, 2019

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

May 24, 2018

AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®